Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colorectal Cancer Liver Metastases Clear all
Recruiting Early Phase 1 Interventional

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

NCT07172282
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Nelitolimod
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Early Phase 1 Interventional Results available

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

NCT00835679
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cetuximab, dasatinib, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Tampa, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 9, 2026, 10:47 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

NCT00107861
View directory record Official record
Conditions
Colorectal Carcinoma, Metastases
Interventions
Ad.hIFN-β (BG00001, IDEC-201)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Oct 9, 2026, 10:47 PM EDT
Not listed Phase 1Phase 2 Interventional

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

NCT00553683
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
cyclophosphamide, poly ICLC, hepatic artery embolization, 3-dimensional conformal radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 9, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 9, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

NCT05195710
View directory record Official record
Conditions
Metastases
Interventions
Yttrium-90 (Y-90) resin microspheres
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Withdrawn Phase 2 Interventional

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

NCT03340558
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Atezolizumab, Cobimetinib
Biological · Drug
Lead sponsor
Niharika Mettu
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

NCT05375604
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver
Interventions
CDK-004
Drug
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Duarte, California • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Phase 3 Interventional Results available

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

NCT01189227
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Postoperative chemotherapy, Perioperative chemotherapy
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
283
States / cities
Antioch, California • Duarte, California • Fremont, California + 210 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

NCT04458259
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
PF-07265807, Sasanlimab, Axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

NCT00008294
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 9, 2026, 10:47 PM EDT
Completed No phase listed Observational

Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies

NCT05462314
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, Liver Cancer, Biliary Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

NCT00001576
View directory record Official record
Conditions
Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
Interventions
Melphalan, Floxuridine, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

NCT04701476
View directory record Official record
Conditions
Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

NCT04796818
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Diffusion Weighted Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 10:47 PM EDT